

STATE OF OKLAHOMA

2nd Session of the 47th Legislature (2000)

HOUSE
RESOLUTION HR1069

By: Gray

AS INTRODUCED

A Resolution relating to the Oklahoma Health Care Authority; recognizing the need for a study of the product-based prior authorization system of pharmacy benefits; recognizing the agreement that the Oklahoma Health Care Authority conduct such study and forego promulgating certain rules until a certain time; and directing distribution.

WHEREAS, the Legislature recognizes the increasing costs of health care; and

WHEREAS, the Legislature recognizes the need for access to health care services, particularly for Medicaid recipients; and

WHEREAS, the Legislature recognizes the benefit of pharmaceuticals in the prevention and treatment of medical conditions and the reduction of medical costs; and

WHEREAS, the Legislature has created the Oklahoma Medicaid Pharmacy Task Force to review and study the delivery of pharmaceuticals to Medicaid beneficiaries; and

WHEREAS, the Oklahoma Health Care Authority has and will continue to study the total fiscal and patient impact of its product-based prior authorization program.

NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE 2ND SESSION OF THE 47TH OKLAHOMA LEGISLATURE:

THAT it is the sense of the House of Representatives that the above-referenced studies be conducted cooperatively by:

1. Sharing statistical data and other information;

2. Seeking input from physicians and other caregivers, including but not limited to those who provide care to Medicaid recipients in nursing homes; and

3. Requesting the assistance of various providers, including but not limited to pharmacists and pharmaceutical manufacturers.

THAT it is the sense of the House of Representatives that the Oklahoma Health Care Authority not add new pharmaceutical categories to the product-based prior authorization system prior to the convening of the 48th Legislature and the completion of the above-referenced studies.

THAT copies of this resolution shall be sent to the Oklahoma Health Care Authority and to the Pharmaceutical Research and Manufacturers of America.

47-2-9655 SK 6/12/15